Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: Randomised controlled trial

BMJ (Online)

Volumn 341, Issue 7770, 2010, Pages

  Chen, Eric Y H ^a   Hui, Christy L M ^a   Lam, May M L ^a   Chiu, Cindy P Y ^a   Law, C W ^b   Chung, Dicky W S ^c   Tso, Steve ^d   Pang, Edwin P F ^c   Chan, K T ^d   Wong, Y C ^c   Mo, Flora Y M ^c   Chan, Kathy P M ^e   Yao, T J ^a   Hung, S F ^e   Honer, William G ^f  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c TAI PO HOSPITAL   (Hong Kong)

^d CASTLE PEAK HOSPITAL   (Hong Kong)

^e KWAI CHUNG HOSPITAL   (Hong Kong)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AKATHISIA; AMENORRHEA; ARTICLE; ASTHENIA; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HONG KONG; HUMAN; LASSITUDE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL STRESS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SALIVATION; SIDE EFFECT; SLEEP PATTERN; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84859002685     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4024     Document Type: Article

References (48)

1. Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Res 2005;31:705-22.
2. Lieberman JA, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al. Time course and biologic correlates of treatment response in firstepisode schizophrenia. Arch Gen Psychiatry 1993;50:369-76. (Pubitemid 23143126)
3. Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7.
4. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29.
5. Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996;14(suppl 3):13-21S. (Pubitemid 26096725)
6. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995;52:173-88.
7. Csernansky JG, Mahmoud R, Brenner R, for the Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl JMed 2002;346:16-22.
8. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22.
9. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Rev 2000;31:371-84. (Pubitemid 30136193)
10. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia II: a randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120-7.
11. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982;39:70-3.
12. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatry Res 1998;32:243-50.
13. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. American Psychiatric Association, 2004.
14. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005;39:1-30.
15. Kane JM, Leucht S. Unanswered questions in schizophrenia clinical trials. Schizophr Bull 2008;34:302-9. (Pubitemid 351323331)
16. Wyatt RJ. Risks of withdrawing antipsychotic medications. Arch Gen Psychiatry 1995;52:205-8.
17. Carpenter WT. Maintenance therapy of persons with schizophrenia. J Clin Psychiatry 1996;57(suppl 9):10-8S.
18. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002;57:209-19.
19. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158:1835-42. (Pubitemid 33054776)
20. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007;68:654-61. (Pubitemid 46841847)
21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
22. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002;106:286-90.
23. Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 2003;63:2265-83.
24. Chen E. Developing an early intervention service in Hong Kong. In: Ehmann T, MacEwan GW, Honer WG, eds. Best care in early psychosis intervention: global perspectives. Taylor and Francis, 2004:125-30.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. American Psychiatric Association, 1994.
26. So E, Kam I, Leung CM, Chung D, Liu Z, Fong S. The Chinese-bilingual SCID-I/P project: stage 1 - reliability for mood disorders and schizophrenia. Hong Kong J Psychiatry 2003;13:7-18.
27. Guy W. Clinical global impression scale (CGI). In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Revised ed. Dept of Health, Education and Welfare, National Institute of Mental Health, 1976:217-22.
28. Berger GE, Proffitt TM, McConchie M, Kerr M, Markelev C, Yuen HP, et al. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. J Clin Psychiatry 2008;69:1702-14.
29. Vaughn CE, Snyder KS, Jones S, Freeman WB, Falloon IR. Family factors in schizophrenic relapse: replication in California of British research on expressed emotion. Arch Gen Psychiatry 1984;41:1169-77. (Pubitemid 15215484)
30. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992;149:1148-56.
31. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982;8:470-84.
32. Foerster A, Lewis S, Owen M, Murray R. Pre-morbid adjustment and personality in psychosis: effects of sex and diagnosis. Br J Psychiatry 1991;158:171-6.
33. Andreasen NC. The scale for the assessment of negative symptoms (SANS). University of Iowa, 1983.
34. Andreasen NC. The scale for the assessment of positive symptoms (SAPS). University of Iowa, 1984.
35. Amador XF, Flaum M, Andreasen NC, Strauss DH, Yale SA, Clark S, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry 1994;51:826-36. (Pubitemid 24313308)
36. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):1-100S.
37. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
38. Guy W. Abnormal involuntary movements scale (AIMS). In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Revised ed. Dept of Health, Education and Welfare, National Institute of Mental Health, 1976:534-7.
39. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(suppl 212):11-9S.
40. Collett D. Modelling survival data in medical research. 1st ed. Chapman and Hall, 1994.
41. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319:670-4. (Pubitemid 29423954)
42. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer 2003;89:781-6.
43. Lin D, Wei L, Ying Z. Checking the Coxmodel with cumulative sums of martingale-based residuals. Biometrika 1993;80:557-72.
44. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
45. Park G, Hadzi-Pavlovic, D. Expressed emotion as a predictor of schizophrenic relapse: an analysis of aggregated data. Psychol Med 1990;20:961-5.
46. Lau JTF, Kim KH, Tsui HY. Prevalence, health outcomes, and patterns of psychotropic substance use in a Chinese population in Hong Kong: a population-based study. Subst Use Misuse 2005;40:187-209.
47. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050-60.
48. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97. (Pubitemid 351418005)